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Abstract
Introduction: The presence of anti-topoisomerase I (topo I) antibodies is a classic scleroderma (SSc) marker
presumably associated with a unique clinical subset. Here the clinical association of anti-topo I was reevaluated in
unselected patients seen in a rheumatology clinic setting.
Methods: Sera from the initial visit in a cohort of unselected rheumatology clinic patients (n = 1,966, including 434
systemic lupus erythematosus (SLE), 119 SSc, 85 polymyositis/dermatomyositis (PM/DM)) were screened by
radioimmunoprecipitation. Anti-topo I-positive sera were also tested with immunofluorescence and RNA
immunoprecipitation.
Results: Twenty-five (15 Caucasian, eight African American, two Latin) anti-topo I positive patients were identified,
and all except one met the ACR SSc criteria. Coexistence of other SSc autoantibodies was not observed, except for
anti-U1RNP in six cases. When anti-topo I alone versus anti-topo I + U1RNP groups were compared, African
American (21% vs. 67%), overlap with SLE (0 vs. 50%; P = 0.009) or PM/DM (0 vs. 33%; P = 0.05) or elevated
creatine phosphokinase (CPK) (P = 0.07) were more common in the latter group. In comparison of anti-topo I-
positive Caucasians versus African Americans, the latter more frequently had anti-U1RNP (13% vs. 50%), mild/no
skin changes (14% vs. 63%; P = 0.03) and overlap with SLE (0 vs. 38%; P = 0.03) and PM/DM (0 vs. 25%; P = 0.05).
Conclusions: Anti-topo I detected by immunoprecipitation in unselected rheumatology patients is highly specific
for SSc. Anti-topo I coexisting with anti-U1RNP in African American patients is associated with a subset of SLE
overlapping with SSc and PM/DM but without apparent sclerodermatous changes.
Introduction
Autoantibodies to topoisomerase I (topo I, also known
as Scl-70) is an established serologic marker of sclero-
derma (systemic sclerosis, SSc) and associated with dif-
fuse scleroderma and severe interstitial lung disease
(ILD) [1-3]. It is highly specific for SSc when tested with
standard double immunodiffusion [4,5]; however, several
studies using enzyme-linked immunosorbent assay
(ELISA) reported high prevalence of anti-topo I in
systemic lupus erythematosus (SLE) [6-9], causing con-
fusion and controversies [10,11]. SSc could start from
the Raynaud’s phenomenon (RP), preceding the onset of
SSc for many years, ILD, arthritis, and others [12].
Because autoantibodies are usually produced before typi-
cal clinical manifestations, it would not be a surprise to
find anti-topo I in undifferentiated connective tissue dis-
ease (UCTD), undiagnosed patients [5], or even in cer-
tain patients with SLE who are going to develop SSc
later [13]. The clinical association of anti-topo I was ree-
valuated based on radioimmunoprecipitation screening
of sera from a cohort of unselected population in a
rheumatology clinic that includes undiagnosed patients
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to established systemic autoimmune rheumatic diseases,
such as SSc, SLE, polymyositis/dermatomyositis (PM/
DM), and rheumatoid arthritis (RA).
Materials and methods
Patients
All 1,966 subjects enrolled in the University of Florida
Center for Autoimmune Diseases (UFCAD) registry
from 2000 to 2010 were studied. Diagnoses of the
patients include 434 SLE, 85 PM/DM, 119 SSc, 35 RA,
and 40 Sjögren syndrome (SS). Clinical findings of
patients at each visit were evaluated and recorded by
the rheumatologists at the Center, following the stan-
dard rheumatology clinic evaluation forms of the
UFCAD. Diagnoses of patients were by the American
College of Rheumatology (ACR) classification criteria for
SLE [14,15], SSc [16], and RA [17], the revised European
criteria by the American-European Consensus Group for
SS [18], and the Bohan’s criteria for PM/DM [19].
Mixed connective tissue disease (MCTD) [20] is not
classified separately, and SSc patients discussed in this
report include patients who also fulfill criteria of other
diagnoses (overlap syndrome). ILD was defined by chest
radiograph and/or high-resolution computed tomogra-
phy (HRCT). The protocol was approved by the Institu-
tional Review Board (IRB). This study meets and is in
compliance with all ethical standards in medicine, and
informed consent was obtained from all patients accord-
ing to the Declaration of Helsinki.
Autoantibody analysis
Autoantibodies in sera from the initial visit of each
patient were screened by immunoprecipitation (IP)
using [
35S]-methionine-labeled K562 cell extract [21].
RNA components of autoantigens were analyzed with
silver staining (Silver Stain Plus; Bio-Rad, Hercules, CA).
ACA were examined by immunofluorescence antinuc-
lear antibodies (ANAs) using HEp-2 slides from INOVA
Diagnostics (San Diego, CA) and a 1:80-diluted serum.
Statistical analysis
Prevalence of autoantibodies and clinical manifestation
was compared by Fisher Exact test using Prism 5.0 for
Macintosh (GraphPad Software, Inc., San Diego, CA). A
value of P < 0.05 was considered significant.
Results
Detection of anti-topoisomerase I and prevalence of anti-
topo I in SSc and SLE
Anti-topo I antibodies were detected in 25 (1.3%) of
1,966 subjects enrolled to University of Florida Center
for Autoimmune Diseases. Prevalence of anti-topo I in
the SSc cohort was 21% (25 of 119); 18% (15 of 85) in
Caucasians, 31% (eight of 25) in African Americans, and
25% (two of eight) in Hispanics. An SSc patient of
mixed ethnic background did not have anti-topo I.
None of the anti-topo I-positive sera had other SSc-spe-
cific autoantibodies [3], including anti-RNA polymerase
(RNAP) I/III, PM-Scl, or Ku by IP; ACA by immuno-
fluorescence; or anti-U3RNP/fibrillarin or anti-Th/To by
RNA analysis from IP. However, six of 25 anti-topo I-
positive sera had coexisting anti-U1RNP antibodies, two
with anti-Sm. Analysis of protein (Figure 1a, b) and
RNA components (Figure 1c) by IP are shown.
Anti-topo I + U1RNP was common in African Ameri-
can (four (16%) of 25) but rare in Caucasian SSc (two
(2%) of 85; P = 0.02 by the Fisher Exact test). In patients
who fulfilled the ACR SLE criteria, anti-topo I was
found in three (2%) of 153 in African American, all
three cases with anti-U1RNP (two with anti-Sm) and as
SLE-SSc overlap syndrome. None of 208 Caucasian or
44 Latin SLE had anti-topo I by IP. Thus, even in unse-
lected patients at our rheumatology clinic, anti-topo I by
IP is highly specific for SSc and SSc overlap syndrome.
Clinical manifestations of patients with anti-topo I versus
anti-topo I + U1RNP
Clinical manifestations of 19 patients with anti-topo I
versus six patients with anti-topo I + U1RNP were com-
pared (Table 1). All patients fulfilled the ACR SSc classi-
fication criteria except for a 48-year-old Caucasian
woman with RP, ILD, and polyarthritis. No scleroderma-
tous changes were noted, and she may be considered sys-
temic sclerosis sine scleroderma. The anti-topo I group
was 68% Caucasian, whereas 67% of anti-topo I +
U1RNP group was African American (P = 0.059). Two of
the anti-topo I + U1RNP patients were also positive for
anti-Sm (P = 0.05; Figure 1). Proximal scleroderma was
common (79%) in anti-topo I group. In contrast, three
(50%) of six anti-topo I + U1RNP patients had no sclero-
dermatous skin changes (P = 0.03). Overlap with SLE or
PM/DM and elevation of creatine phosphokinase (CPK)
were common in anti-topo I + U1RNP group (P = 0.009
for SLE, P = 0.07 for CPK, P = 0.05 for PM/DM; Table 1).
Clinical features of six cases of anti-topo I with anti-
U1RNP are summarized (Table 2). In four African
American patients, case 2 had diffuse cutaneous sclero-
derma (dcSSc) but the other three did not have sclero-
dermatous skin changes; they fulfilled ACR classification
criteria for SSc based on pitting scars and ILD. Overlap
of SSc with SLE or PM/DM was seen in three African
American cases.
Racial difference in anti-topo I-positive scleroderma
patients
Clinical features of Caucasian versus African American
patients with anti-topo I were compared (Table 3). In
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Page 2 of 6serology, four (50%) of eight of African Americans with
anti-topo I had coexisting anti-U1RNP, two with anti-
Sm, but this was only in two (13%) of 15 Caucasians.
Proximal scleroderma was noted in 87% of Caucasians
but only in 38% of African Americans (P =0 . 0 3 ) .T h r e e
of eight African American anti-topo I-positive patients
did not have sclerodermatous changes, and two had
sclerodactyly only (P = 0.03, no skin changes and sclero-
dactyly only combined). Overlap with SLE and elevated
CPK (P = 0.03 versus Caucasians) and overlap with PM/
DM (p = 0.05) were also common in African Americans.
Lack of skin changes, and overlap with SLE and PM/
DM are common in African American patients with
anti-topo I + U1RNP but not anti-topo I antibodies
alone. These clinical features were not present in two
cases of anti-topo I + U1RNP in Caucasians, suggesting
that this clinical subset may be relatively unique to Afri-
can Americans.
Figure 1 Coexistence of anti-snRNPs antibodies in anti-topo I-positive sera. (a)12.5% SDS-PAGE. (b) 8% SDS-PAGE. Six sera with anti-topo I
and-snRNPs (two anti-Sm + U1RNP; four anti-U1RNP) were identified by immunoprecipitation of [
35S]-methionine-labeled K562 cell extract.
Positions of Topo I, components of snRNPs (U5RNP-200 kDas; U1-70 kDa; U1-A, B’/B, U1-C, D1/D2/D3, E, F, and G), and molecular weight are
indicated. U1, Sm, Topo I, prototype sera for each specificity; Topo I+Sm, anti-topo I with anti-Sm and U1RNP-positive SSc sera; Topo I+U1RNP,
anti-topo I and U1RNP-positive SSc sera; NHS, normal human serum. (c) Analysis of RNA components in anti-topo I-positive patients with
coexisting anti-snRNPs. RNA components immunoprecipitated by human autoimmune sera were analyzed with urea-PAGE and silver staining. Six
anti-topo I-positive patients had coexisting anti-UsnRNPs (two anti-Sm (U1, 2, 4 to 6, and 5; lanes 1 and 2) and four anti-U1RNP (lanes 3 to 6))
were identified. Total, total RNAs; U1, Sm, prototype human serum for each specificity; Topo I + Sm, anti-topo I with anti-Sm and U1RNP-positive
SSc sera; Topo I + U1RNP, anti-topo I and U1RNP-positive SSc sera; NHS, normal human serum; positions of 7S, 5.8S, and 5S rRNA, tRNAs, and U1,
2, 4, 5, and 6 snRNAs are shown.
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A n t i - t o p oIi sah i g h l ys p e c i f i cd i s e a s em a r k e ro fS S c
when tested by immunodiffusion [4,5] or IP as in the
present study. It can be occasionally found in undiag-
n o s e dp a t i e n t ss u c ha sU C T D[ 2 2 ]o rR P[ 5 ] ,a tl e a s t
partially, because autoantibodies are usually produced
before clinical manifestation [23]. In one study, anti-
topo I were tested by ELISA in 2,181 unselected indivi-
duals to find none was positive [24]. All these data sup-
port the high specificity of anti-topo I for SSc.
Reports on high prevalence of anti-topo I in SLE by
ELISA and its association with SLE activity and nephritis
[8,9] challenged the general observation on SSc specifi-
city of anti-topo I and triggered much confusion and
many controversies [5,10,11]. When we tested 46 SLE
sera (from Louisiana, not included in the present study)
by a commercial anti-topo I ELISA, 41% were positive;
however, only two of 19 were IP positive [10]. In the
study that had 32 (25%) of 128 prevalence of anti-topo I
in SLE [8], only four of 32 ELISA positives were double
immunodiffusion positive, and data supporting the spe-
cificity of ELISA were limited. Some also reported 13%
to 29% prevalence of anti-topo I in SLE [6,7,9,25]
whereas others reported low prevalence by ELISA [5,11].
Thus, the prevalence of anti-topo I in SLE appears to
depend on the source of antigens or ELISA kits. In
some studies [8-10], anti-topo I ELISA positives in SLE
are detecting antibodies that are different from those
detected by immunodiffusion and IP. False positives
caused by anti-dsDNA/chromatin antibodies in SLE sera
Table 1 Clinical manifestations of anti-topo I in African
American versus Caucasian patients
Specificity Topo I
(n = 19)
Topo I + U1RNP
(n =6 )
P
Age (yr, mean ± SD) 55.10 ± 12.9 46.6 ± 8.6
Male 26% 17%
Caucasian 68% 33%
African American 21% 67% 0.059
Latin 11% 0
Anti-Sm 0 33% 0.05
Proximal scleroderma 79% 50%
No sclerodermatous changes 5% 50% 0.03
Sclerodactyly only 16% 0
Pitting scars 74% 83%
ILD 74% 83%
Scleroderma kidney 16% 0
Overlap with SLE 0 50% 0.009
Elevated CPK 11% 50% 0.07
Overlap with PM/DM 0 33% 0.05
CPK, creatine phosphokinase; ILD, interstitial lung disease. P values are with
the Fisher Exact test.
Table 2 Clinical characteristic of six cases with anti-topo I coexisting with anti-snRNPs autoantibodies
Case 1 2 3 4 5 6
Anti-snRNPs Sm, U1RNP Sm, U1RNP U1RNP U1RNP U1RNP U1RNP
Race Afr Am Afr Am Afr Am Afr Am Caucasian Caucasian
Type of skin involvement No scl dcSSc No scl No scl dcSSc dcSSc
Pitting scars Y Y Y Y Y
ILD Y Y Y Y Y
Raynaud phenomenon Y Y Y Y Y Y
Pulmonary hypertension Y
Esophageal dysmotility Y
Flexion contracture Y Y
Acro-osteolysis Y P
SLE overlap/number of ACR criteria Y
6
Y
5
N
2
Y
5
N
2
N
2
PM/DM overlap Elevated CPK DM PM
Afr Am, African American; dcSSc, diffuse cutaneous scleroderma; F, female; ILD, interstitial lung disease; M, male; Y, present; N, not present; No Scl, no
sclerodermatous skin changes; P, possible.
Table 3 Clinical manifestations of African American
versus Caucasian patients with anti-topo I
Caucasian
(n = 15)
African American
(n =8 )
P
Age (yr, mean ± SD) 56.5 ± 11.5 45.9 ± 13.2
Male 20% 38%
Anti-U1RNP 13% 50% 0.13
Anti-Sm 0 25%
Proximal scleroderma 87% 38% 0.03
No skin changes 7% 38% 0.03
a
Sclerodactyly only 7% 25%
Pitting scar 80% 88%
ILD 73% 75%
Scleroderma kidney 20% 0
Overlap with SLE 0 38% 0.03
Elevated CPK 7% 50% 0.03
Overlap with PM/DM 0 25% 0.05
aNo skin changes and sclerodactyly combined. CPK, creatine phosphokinase;
ILD, interstitial lung disease. P values are with the Fisher Exact test.
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such as Ku and replication protein A, are well documen-
ted [10,26]. Thus, the most likely explanation appears to
be that anti-topo I ELISA positives in SLE are false posi-
tives caused by antibodies to DNA/chromatin. Because
topo I is a nucleotide sequence nonspecific DNA-bind-
ing protein, one scenario is that serum DNA binds to
topo I coated on plate, and this is followed by anti-
DNA/chromatin antibodies binding to DNA. A second
scenario is that preformed serum anti-DNA/chromatin
immune complex can bind to topo I via its DNA com-
ponent. It is also possible that anti-topo I ELISA posi-
tives in SLE in some studies reflect detection of low-
affinity antibodies or antibodies other than IgG class
because of secondary antibody specificity. Alternatively,
certain ELISA antigens may contain impurities as unre-
lated antigens, or some SLE sera recognize denatured
topo I epitopes not present in native molecules and thus
appear unreactive (negative) in immunodiffusion or IP.
Anti-topo I antibodies are positive in 1% to 3% of SLE
patients, even by reliable methods such as immunodiffu-
sion [8]. This may be explained by SLE-SSc overlap syn-
drome, not typical pure SLE [10,27], as shown in the
present study. Thus, anti-topo I by immunodiffusion or
IP is specific for SSc, and cautious interpretation is
required for anti-topo I ELISA positive results in SLE.
SSc patients can be classified based on autoantibody
specificities that are associated with unique clinical sub-
sets [3]. Coexistence of SSc-related autoantibodies is
uncommon [3]; however, a combination of anti-topo I
and anti-U1RNP appears to be an interesting and possi-
bly clinically useful exception. In addition to cases
reported mainly from Japan [27-29], frequent association
of anti-topo I and anti-U1RNP in a large Japanese and
American cohorts also was observed [1,2]. In one study,
nine (12%) of 78 of anti-topo I-positive SSc had coexist-
ing anti-U1RNP, and an additional three later developed
anti-U1RNP [1]. Three patients in this cohort also had
a n t i - S ma n t i b o d i e s[ 2 7 ] .As t u d yf r o mF i n l a n dr e p o r t e d
12% of coexistence of anti-topo I and anti-U1RNP [30].
Detection of anti-topo I in MCTD patients indicates
coexisting anti-topo I and anti-U1RNP [31]. Regarding
the issue of race and coexistence of these two specifici-
ties in SSc, the prevalence was reported as 2% in Cauca-
sian, 13% in African American, and 16% in Japanese in
another U.S. cohort [2]. The 50% prevalence of anti-
U1RNP in anti-topo I-positive African Americans in the
present study is higher than that in other studies to
date. Furthermore, prevalence of diffuse scleroderma in
African Americans was low versus that in the previous
study [2]. Three of four cases of anti-topo I + U1RNP-
positive African American patients can be classified as
SSc by using the ACR criteria based on the presence of
pitting scars and ILD [16]; however, they lack
sclerodermatous skin changes. Thus, this subset of
patients might not be included in the studies that
selected SSc patients based on diagnosis by physicians
[2,32,33], sclerodactyly as a minimum requirement [34],
or by using other SSc criteria [35]. They can be easily
classified as “SLE with ILD and RP” because this is the
common pattern of presentation among anti-U1RNP-
positive SLE or MCTD. This subset could also be real
anti-topo I-positive SLE without features of SSc
described in some literature [8]. It may be clinically
important to identify anti-topo I, in addition to anti-
U1RNP, in these patients, because the former could be
associated with severe ILD and scleroderma renal crisis
[2,3].
Conclusions
Anti-topo I detected by IP in unselected rheumatology
patients is highly specific for SSc. Anti-topo I and anti-
U1RNP frequently coexist in African American patients,
and they are associated with a subset of overlap syn-
drome of SLE, SSc, and PM/DM, characterized by RP,
pitting scars, and ILD without sclerodermatous changes.
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